• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

WILEX

edit

WILEX AG, a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company’s products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.

Milestones

edit

• 
  WILEX added Peter Llewellyn-Davies as CFO.
  Posted 6/13/10 at 11:07pm
• 
  WILEX added Olaf G Wilhelm as Chairman & CEO.
  Posted 6/13/10 at 11:07pm
• 
  Went public with stock symbol XTRA:WL6.
  Posted 7/20/10 at 5:35pm
• 
  WILEX received $27.1M in Venture Round funding. (3/23/10)
  Posted 7/20/10 at 5:34pm via wilex.de

Videos

Screenshots

edit

Stock Price

Sources

1. WILEX AG secures financing up to EUR 20 million through an equity line (wilex.de) [edit]